GliomaNCT07699172
EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
A study testing EEG-Based Neural Signal Decoding Strategy in people with Glioma and Brain Neoplasm, run by Bo Wang at 1 site in China.
Trial summary
Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal decoding strategy for cognitive function preservation in patients undergoing brain tumor… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Glioma, Brain Neoplasm, Brain Tumor Adult
- What is being tested?
- EEG-Based Neural Signal Decoding Strategy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2026to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years to 75 years.
- Patients diagnosed with brain glioma and scheduled for surgical treatment.
- Conscious and able to understand study procedures.
- Able to complete neuropsychological assessments.
- Willing to participate and provide written informed consent.
Who cannot join
- Severe dysfunction of major organs (heart, lung, liver, or kidney).
- Severe psychiatric disorders or cognitive impairment.
- Severe language impairment preventing completion of study procedures.
- Any other condition judged by the investigator to make participation inappropriate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tianjin Huanhu Hospital
Tianjin, Tianjin Municipality, 300350
Bo Wang, 022-59065262, dr.bo.wang@tmu.edu.cn
About this study
Official title: A Prospective Single-Arm Study of EEG-Based Neural Signal Decoding for Cognitive Function Preservation in Patients Undergoing Brain Tumor Surgery
Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal decoding strategy for cognitive function preservation in patients undergoing brain tumor surgery. Participants will undergo standardized neuropsychological assessments together with preoperative, intraoperative, and postoperative electrophysiological recordings. The study will investigate whether EEG-based neural decoding can improve objective cognitive function assessment and support individualized functional preservation during brain tumor surgery.
Read the detailed description
This is a prospective, single-center, single-arm interventional study designed to investigate an EEG-based neural signal decoding strategy for higher-order cognitive function preservation in patients undergoing brain tumor surgery.
Eligible patients with brain tumors scheduled for surgical treatment will be enrolled. Participants will receive standardized neuropsychological assessments before and after surgery. High-density EEG recordings will be acquired during different stages of the perioperative period, including task-based and resting-state paradigms when applicable. Neural signal decoding methods will be used to extract cognitive-related electrophysiological features and evaluate their association with postoperative cognitive outcomes.
The primary objective is to evaluate the feasibility of EEG-based neural signal decoding for objective cognitive assessment and functional preservation during brain tumor surgery. Secondary objectives include exploring the relationship between electrophysiological biomarkers and neuropsychological performance, evaluating perioperative cognitive changes, and providing preliminary evidence for individualized cognitive protection strategies in brain tumor patients.
- Conditions
- Glioma, Brain Neoplasm, Brain Tumor Adult
- Being tested
- EEG-Based Neural Signal Decoding Strategy
- Keywords
- Electroencephalography, EEG, Neural Signal Decoding, Cognitive Function, Cognitive Preservation, Brain Tumor Surgery
- Medical subject headings
- Glioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EEG-Based Neural Signal Decoding StrategyProcedure or surgery
EEG-based neural signal decoding will be performed during the perioperative period to identify cognitive functional networks and assist individualized cognitive function preservation during brain tumor surgery.
| Study group | Role | What they receive |
|---|---|---|
| EEG-Guided Cognitive Function Preservation | Experimental | Participants undergoing brain tumor surgery will receive the EEG-based neural signal decoding strategy in addition to standard surgical management for individualized cognitive function preservation. Cognitive outcomes will be evaluated using standardized neuropsychological assessments. Receives: Procedure: EEG-Based Neural Signal Decoding Strategy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mini-Mental State Examination (MMSE) Total Score
Cognitive function assessed using the Mini-Mental State Examination (MMSE). The total score ranges from 0 to 30, with higher scores indicate better cognitive function.
Measured: Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months
Montreal Cognitive Assessment (MoCA) Total Score
Cognitive function assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicate better cognitive function.
Measured: Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion31 Jul 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bo Wang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Bo Wang, Huanhu Hospital Affiliated to Tianjin Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07699172
- Sponsor's protocol ID
- 2026-BRAIN-TUMOR-COG-01
- Status last verified
- Jul 2026
- First submitted
- 3 Jul 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The plan for sharing individual participant data has not yet been determined. Data sharing will be considered after study completion in accordance with institutional policies and applicable regulations.
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single-Arm Study of EEG-Based Neural Signal Decoding for Cognitive Function Preservation in Patients Undergoing Brain Tumor Surgery
- ClinicalTrials.gov ID
- NCT07699172
- Acronym / sponsor ID
- 2026-BRAIN-TUMOR-COG-01
- Conditions
- Glioma, Brain Neoplasm, Brain Tumor Adult
- Keywords
- Electroencephalography, EEG, Neural Signal Decoding, Cognitive Function, Cognitive Preservation, Brain Tumor Surgery
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Bo WangUniversity, hospital or other
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 31 Jul 2028 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brain tumors and their surgical treatment may impair cognitive function, affecting patients' quality of life. This prospective single-arm study aims to evaluate the feasibility and clinical utility of an EEG-based neural signal decoding strategy for cognitive function preservation in patients undergoing brain tumor surgery. Participants will undergo standardized neuropsychological assessments together with preoperative, intraoperative, and postoperative electrophysiological recordings. The study will investigate whether EEG-based neural decoding can improve objective cognitive function assessment and support individualized functional preservation during brain tumor surgery.
Detailed description
This is a prospective, single-center, single-arm interventional study designed to investigate an EEG-based neural signal decoding strategy for higher-order cognitive function preservation in patients undergoing brain tumor surgery.
Eligible patients with brain tumors scheduled for surgical treatment will be enrolled. Participants will receive standardized neuropsychological assessments before and after surgery. High-density EEG recordings will be acquired during different stages of the perioperative period, including task-based and resting-state paradigms when applicable. Neural signal decoding methods will be used to extract cognitive-related electrophysiological features and evaluate their association with postoperative cognitive outcomes.
The primary objective is to evaluate the feasibility of EEG-based neural signal decoding for objective cognitive assessment and functional preservation during brain tumor surgery. Secondary objectives include exploring the relationship between electrophysiological biomarkers and neuropsychological performance, evaluating perioperative cognitive changes, and providing preliminary evidence for individualized cognitive protection strategies in brain tumor patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| EEG-Guided Cognitive Function Preservation | Experimental | Procedure: EEG-Based Neural Signal Decoding StrategyParticipants undergoing brain tumor surgery will receive the EEG-based neural signal decoding strategy in addition to standard surgical management for individualized cognitive function preservation. Cognitive outcomes will be evaluated using standardized neuropsychological assessments. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 18 years to 75 years.
- Patients diagnosed with brain glioma and scheduled for surgical treatment.
- Conscious and able to understand study procedures.
- Able to complete neuropsychological assessments.
- Willing to participate and provide written informed consent.
Key exclusion criteria (4 listed)
- Severe dysfunction of major organs (heart, lung, liver, or kidney).
- Severe psychiatric disorders or cognitive impairment.
- Severe language impairment preventing completion of study procedures.
- Any other condition judged by the investigator to make participation inappropriate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EEG-Based Neural Signal Decoding StrategyEEG-based neural signal decoding will be performed during the perioperative period to identify cognitive functional networks and assist individualized cognitive function preservation during brain tumor surgery. | Procedure or surgery | EEG-Guided Cognitive Function Preservation |
Primary outcome
Mini-Mental State Examination (MMSE) Total Score
Time frame: Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months
Cognitive function assessed using the Mini-Mental State Examination (MMSE). The total score ranges from 0 to 30, with higher scores indicate better cognitive function.
Montreal Cognitive Assessment (MoCA) Total Score
Time frame: Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months
Cognitive function assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicate better cognitive function.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Individual participant dataSharing planned: Undecided. The plan for sharing individual participant data has not yet been determined. Data sharing will be considered after study completion in accordance with institutional policies and applicable regulations.
Related trials for Glioma
RecruitingPhase 1
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Glioblastoma Multiforme, Recurrent Glioblastoma
Not yet recruitingEarly Phase 1
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
Glioma
RecruitingPhase 2
A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
RecruitingPhase 1
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Adult Glioblastoma, High Grade Glioma
Not yet recruitingPhase 1
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
High-grade Glioma, Diffuse Intrinsic Pontine Glioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EEG-Based Neural Signal Decoding Strategy in people with Glioma and Brain Neoplasm, run by Bo Wang at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bo Wang (022-59065262, dr.bo.wang@tmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mini-Mental State Examination (MMSE) Total Score (time frame: Baseline, postoperative 1 week, postoperative 1 month, and postoperative 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.